Promega Corporation

P450-Glo™ CYP3A4 Biochemical and Cell-Based Assays

Share

  • Share
  • Print
  • Email
  • Download PDF

Abstract

The bioavailability and clearance of most therapeutic drugs are primarily mediated by cytochrome P450 enzymes, and adverse drug-drug interactions frequently occur because of altered P450 activities. In this article, we describe cytochrome P450 assays that can predict both P450 induction-based and P450 inhibition-based drug-drug interactions at the earliest stages of drug discovery. We focus on assays for the CYP3A4 enzyme, which accounts for about 30% of the P450 in human liver and oxidizes about half of all drugs that are eliminated after prior metabolism. We have developed three luminogenic P450-Glo™ CYP3A4 substrates: Luciferin-BE, Luciferin-PFBE and Luciferin-PPXE. Each substrate is used as a probe for in vitro biochemical assays of recombinant CYP3A4 to detect P450 inhibition by test compounds. Additionally, Luciferin-PFBE is ideal for cell-based measurements of CYP3A gene inductions by drugs. The cell-based assay is rapid and simple and can be performed in a nonlytic mode that leaves cells intact for additional analysis.

Promega Notes 96, 15–18.

Mary Sobol, Dongping Ma and James J. Cali

Promega Corporation
Publication Date: 2007

Download Article (216 KB)

It appears that you have Javascript disabled. Our website requires Javascript to function correctly. For the best browsing experience, please enable Javascript.

Scientists at Your Service

Scientists at Your Service

We offer a range of services to help you succeed using Promega technologies. From product training to set up of automated systems and development of custom applications—our scientific support goes beyond the basics.

Ask us! We are here to help you.